stockrowMesoblast Limited (MESO) vs Precigen, Inc. (PGEN)
- Mesoblast Limited MESO 13.21 +0.84%
- Precigen, Inc. PGEN 4.54 −2.58%
Mesoblast Limited and Precigen, Inc. are both Biotechnology companies. Mesoblast Limited and Precigen, Inc. are of similar size ($1.7B and $1.7B). Mesoblast Limited has negative trailing earnings, so its P/E is not meaningful; Precigen, Inc. trades at 61.8×. Precigen, Inc. grew revenue faster over the last twelve months: 2,387.6% against −26.5%. Precigen, Inc. has the higher net margin (15.6% vs −1,091.7%) and the higher return on invested capital (15.9% vs 0.00%). Across the 18 metrics below, Precigen, Inc. leads on 12 and Mesoblast Limited on 6.
Valuation
Profitability
| Metric | MESO | PGEN | Biotechnology median |
|---|---|---|---|
| Gross margin | (269.72%) | 91.42% | 67.24% |
| Operating margin | (826.28%) | 21.43% | 0.00% |
| Net margin | (1,091.71%) | 15.55% | 0.00% |
| Free cash flow margin | 0.00% | (47.35%) | 0.00% |
| Return on equity | 0.00% | 38.84% | (50.28%) |
| Return on assets | 0.00% | 12.73% | (45.89%) |
| Return on invested capital | 0.00% | 15.93% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack